Jiahe Bio introduced CDK4/6 inhibitors, And Beida Pharmaceuticals introduced oncology immunotherapy.

Jiahe Biology: CDK4/6 Inhibitor Lerociclib June 22, G1 Therapeutics (G1) and Genor Biopharma announced the development and commercialization of a CDK4/6 inhibitor lerociclib in the Asia Pacific region (except Japan) exclusive license agreement.
under the agreement, G1 will receive an upfront cash payment of $6 million and is eligible for up to $40 million in development and commercial milestone payments.
, Jiahe Bio will pay royalties for different grades of G1 based on the annual net sales of lerociclib.
Jiahe Bio will have the exclusive development and commercialization rights of lerociclib in the Asia Pacific region (except Japan).
Lerociclib, discovered and developed by G1, is a differentiated oral CDK4/6 inhibitor that has been developed for use in combination with other targeted therapies for certain types of breast and lung cancer.
the drug's preliminary clinical data in estrogen receptor-positive, HER2-negative (HER2-) breast cancer patients have proved that its differences with the currentcommercialcd CDK4/6 inhibitors have been demonstrated in the concept of clinical characteristics, in terms of tolerance and neutrophil reduction.
neutrophila is one of the main toxicities associated with CDK4/6 inhibition.
currently, the product is currently conducting two Phase 1/2 clinical trials.
", "We found serious unmet medical needs in patients with assisted therapy in Asia HR Plus, HER2-metastatic breast cancer.
especially in middle- and high-risk patients, who have long duration of treatment and need better tolerable treatments.
," commented Dr. Guo Feng, chief executive officer of Jiahe Bio.
"Lerociclib is a potential best-in-class CDK4/6 inhibitor with powerful efficacy and unique safety compared to commercially available products.
we look forward to working with G1 to maximize the potential of our product in the Asia Pacific region with lerociclib as a strategic fit for our product portfolio.
" Jiahe Bio, an innovative biopharmaceutical company driven by research and development, was founded in 2007.
currently, the company has more than a dozen research products, of which ten products have entered the clinical development phase, mainly in the field of oncology and other major diseases.
June 1, the company just completed a $160 million round B financing.
funds are used for clinical project advancement of existing product pipelines, research and development of early innovative drugs, potential strategic cooperation within and outside China, and preparation for the commercialization of products that are currently in the late stages of research and development.
Beida Pharmaceuticals: PD-1 Antibody Balstilimab and CTLA-4 Antibody Zalrelimab June 22, Beida Pharmaceuticals announced a $35 million partnership with Agenus Inc. to introduce the latter PD-1 antibody balstilimab and CTLA-4 antibody zalrelimab, two tumor-immune monoclonal antibodies.
announced that two monotonicas (a combination of drugs and two drugs) are expected to submit a listing application for refractive cervical cancer indications in the United States this year.
it is worth mentioning that there are no CTLA-4 antibodies approved for listing in China.
under the agreement, Beda Pharmaceuticals will make a $15 million down payment to Agenus, and secure a $20 million cash share offer for Agenus through the Equity Subscription Agreement between Beda Investment (Hong Kong) Limited, and Beida Pharmaceuticals will acquire the exclusive development and commercialization of all adaptations other than the treatment of the bladder in China (including Hong Kong, Macau and Taiwan) and other drugs.
Balstilimab is an all-human monoclonal antibody targeting the program death receptor 1 (PD-1) on T cells for immune checkpoints.
Zalifrelimab is an all-human monoclonal antibody targeting cytotoxic T lymphocyte-related antigen 4 (CTLA-4) targeted at T cell surface expression.
According to the announcement, both mono-drugs (single drug and two drugs combined) showed outstanding efficacy and safety in the mid-term analysis of critical registered clinical studies of refractive cervical cancer.
Agenus plans to submit a listing application to the U.S. FDA this year for the listing of balstilimab monotherapy, as well as balstilimab and zalifrelimab, which are used in a link to refractive cervical cancer indications.
PD-1 and CTLA-4 are both popular and already targeted in the direction of tumor immunotherapy.
, china has a number of PD-1 antibodies have been approved for sale, including Keytruda, Opdivo, Cindili sepal resistance, but has not yet been CTLA-4 antibody market editing.
the introduction of two products, balstilimab and zalifrelimab, will fill the gap in the company's immunonode inhibitors and will further optimize its presence in the field of macromolecule innovative drugs.
"We are pleased to partner with Agenus, a leader in immuno-oncology, as the first step in our long-term strategic partnership."
" Beida PharmaceuticalCoB.co., ltd. Chairman and CEO Dr. Ding Listing believes that, based on convincing clinical data released so far, Agenus' balstilimab and zalifrelimab can provide better treatment options for cervical cancer patients in China.
hopes to further tap and enhance the potential of two projects to treat other types of tumors and to work with the company's existing projects to benefit cancer patients in China.
Agenus is a clinical-phase biotechnology company focused on developing tumor immunotherapy, focusing on the development of innovative anticancer therapies that enhance the body's immune system, including antibodies, vaccines, adjures and cell therapies, with the aim of developing the best combination of these products for the treatment of cancer.
.